Advertisement

Search Results

Advertisement



Your search for all items matches 29193 pages

Showing 1 - 50


ESMO 2022: Updates in Breast Cancer

On this episode, we’re highlighting speakers who presented data in breast cancer during the ESMO Congress 2022. The first speaker discusses patterns of genomic instability in metastatic breast cancer, and the second touches on oncofertility care for young patients with breast cancer.

colorectal cancer
immunotherapy

Julien Taïeb, MD, PhD, on Colorectal Cancer: Recent Findings on Avelumab vs Standard Second-Line Chemotherapy

Julien Taïeb, MD, PhD, of Paris Descartes University, discusses phase II results from the SAMCO-PRODIGE 54 trial, which shows the efficacy and safety of avelumab in the second-line treatment of patients with deficient DNA mismatch–repair microsatellite-instability metastatic colorectal cancer....

issues in oncology

AACR Cancer Progress Report 2022 Shows Cancer Mortality Rates Continue to Decline, but Challenges Remain

Advances in more effective treatment and early detection diagnostics, coupled with reductions in smoking rates, have resulted in a 32% decline in cancer mortality in the United States since 1991, translating into nearly 3.5 million lives saved, according to the newly released American Association...

solid tumors
genomics/genetics

Selpercatinib in RET Fusion–Positive Solid Tumors Other Than Lung or Thyroid Malignancies

As reported in The Lancet Oncology by Vivek Subbiah, MD, and colleagues, the phase I/II LIBRETTO-001 basket trial has shown that the RET kinase inhibitor selpercatinib demonstrated activity in patients with RET fusion–positive solid tumors in an analysis excluding lung and thyroid cancers. Findings ...

September 24 Is World Cancer Research Day

September 24 is World Cancer Research Day, an initiative organized by a collaboration of professional societies, research organizations, and other institutions. In advance of the event, the following declaration was published in order to outline the goals of the initiative: Cancer is projected to...

leukemia

Conditioning With Busulfan/Cyclophosphamide vs Total-Body Irradiation/Cyclophosphamide for B-Cell ALL

In a Chinese phase III trial reported in the Journal of Clinical Oncology, Zhang et al found that conditioning with busulfan plus cyclophosphamide (BuCy) was noninferior to total-body irradiation plus cyclophosphamide (TBI-Cy) in 2-year overall survival among adult patients with standard-risk...

colorectal cancer

Study Shows Many Patients Prefer Stool Test to Colonoscopy for Colorectal Cancer Screening

Three-quarters of surveyed people preferred to do a fecal immunochemical test (FIT) rather than undergo a colonoscopy for their regular colorectal cancer screening, according to a new Cedars-Sinai study published by Makaroff et al in Clinical Gastroenterology and Hepatology. “One of the big issues...

colorectal cancer

Precision Physical Activity Prescriptions May Improve Survival in Patients With Stage III Colon Cancer

Physical activity may be associated with improved outcomes for patients undergoing postoperative treatment for stage III colon cancer, according to findings from a new study out of Pennington Biomedical Research Center published by Brown et al in the Journal of Clinical Oncology. The study assessed ...

lung cancer
pain management

New, Long-Term Opioid Use After Lung Cancer Surgery Linked to Reduced 2-Year Survival

New, long-term use of opioids after lung cancer surgery was linked to a 40% increased risk of death from any cause within the following 2 years, according to findings published by Oh et al in the journal Regional Anesthesia & Pain Medicine. Persistent postoperative pain has been reported in up...

colorectal cancer

MSI-High Rectal Adenocarcinoma

This is Part 4 of Updates in Colorectal Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable.     In this video, Drs. Cathy Eng, Arvind Dasari, and Smitha Krishnamurthi discuss the management of microsatellite instability (MSI)-high rectal...

colorectal cancer

HER2-Positive Colorectal Cancer

This is Part 3 of Updates in Colorectal Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable.     In this video, Drs. Cathy Eng, Arvind Dasari, and Smitha Krishnamurthi discuss the management of HER2-positive colorectal cancer. The patient is a...

colorectal cancer

Role of Neoadjuvant Therapy in T4 Colon Cancer

This is Part 2 of Updates in Colorectal Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable.     In this video, Drs. Cathy Eng, Arvind Dasari, and Smitha Krishnamurthi discuss the role of neoadjuvant therapy in T4 colon cancer. The patient a...

colorectal cancer

Role of Circulating Tumor DNA in Early-Stage Colon Cancer

This is Part 1 of Updates in Colorectal Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable.     In this video, Drs. Cathy Eng, Arvind Dasari, and Smitha Krishnamurthi discuss the role of circulating tumor DNA (ctDNA) in early-stage colon cancer....

kidney cancer

Nizar M. Tannir, MD, on RCC: Data on Bempegaldesleukin Plus Nivolumab vs Tyrosine Kinase Inhibitors in Untreated Disease

Nizar M. Tannir, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III findings from the PIVOT-09 study, which compared bempegaldesleukin plus nivolumab with the investigator’s choice of a tyrosine kinase inhibitor (either sunitinib or cabozantinib) in patients with...

gynecologic cancers

Pafolacianine for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer

In a phase III trial reported in the Journal of Clinical Oncology, Janos L. Tanyi, MD, PhD, and colleagues found that use of pafolacianine infusion for intraoperative imaging improved the detection of lesions in patients with folate receptor–positive ovarian cancer, compared with using white light...

lung cancer
immunotherapy

Adjuvant Pembrolizumab in Patients With Completely Resected Stage IB to IIIA NSCLC

As reported in The Lancet Oncology by O’Brien et al, the second interim analysis of the phase III PEARLS/KEYNOTE-091 trial has shown significantly improved disease-free survival with adjuvant pembrolizumab vs placebo in patients with completely resected stage IB to IIIA non-small cell lung cancer...

genomics/genetics

Selpercatinib Approved for Locally Advanced or Metastatic RET Fusion–Positive Solid Tumors

On September 21, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selpercatinib (Retevmo) for adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion and disease progression on or following prior systemic...

lung cancer
genomics/genetics

FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion–Positive NSCLC

On September 21, the U.S. Food and Drug Administration (FDA) granted regular approval to selpercatinib (Retevmo) for adult patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) with a RET gene fusion (as detected by an FDA-approved test). The FDA also approved the Oncomine ...

skin cancer

New Imaging Technique May Improve Accuracy of Basal Cell Carcinoma Diagnosis

A novel imaging technique may significantly improve the accuracy of the diagnosis of basal cell carcinoma (BCC) compared to clinical and dermoscopic examinations alone, according to new research presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress. The study found...

issues in oncology

Housing Instability and Risk of Mortality in Patients With Cancer

Little is known about patients with cancer’s social welfare and how it affects their health outcomes. To address this, researchers at University of California (UC) San Diego School of Medicine and partnering institutions assessed the prevalence and impact of various social risk factors in patients...

lung cancer
immunotherapy

Neoadjuvant Atezolizumab May Be Safe, Effective Option for Localized Non–Small Cell Lung Cancer

New data show that the immuno-oncology drug atezolizumab may be a safe and effective treatment for patients with stage IB to IIIB non–small cell lung cancer (NSCLC) prior to surgery, according to a study led by researchers with The Ohio State University Comprehensive Cancer Center–Arthur G. James...

skin cancer
immunotherapy

Adjuvant Nivolumab With or Without Ipilimumab in Patients With Resected Stage IV Melanoma With No Evidence of Disease

As reported in The Lancet by Livingstone et al, the final analysis of the German phase II IMMUNED trial showed significantly improved recurrence-free survival with adjuvant nivolumab/ipilimumab and nivolumab alone vs placebo in patients with resected stage IV melanoma who had no evidence of disease ...

colorectal cancer

Association of Distance to Treatment Facility, U.S. Region, and Insurance Status With Diagnosis of Advanced Colon Cancer

In a National Cancer Database analysis reported in JAMA Network Open, Brand et al found that patients with colon cancer who lived farther from their treatment facility and those with no insurance or Medicaid alone were more likely to present with advanced-stage disease. As stated by the...

colorectal cancer
genomics/genetics

ctDNA Analysis of Acquired EGFR Resistance Alterations With First-Line Cetuximab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer

In a circulating tumor DNA (ctDNA) substudy from the CALGB/SWOG-80405/Alliance trial reported in the Journal of Clinical Oncology, Kanwal Raghav, MD, MBBS, and colleagues found that first-line use of the anti-EGFR antibody cetuximab combined with chemotherapy was associated with only a small number ...

pancreatic cancer

Preclinical Study Finds New Synthetic Lethal Agent Could Be Potential Treatment for Pancreatic Cancer

Researchers at The Marvin and Concetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center have found that a new synthetic lethal agent could be an effective treatment for pancreatic cancers with DNA damage repair (DDR) defects. Igor Astsaturov, MD, PhD, a co-director of the Institute...

issues in oncology

Study Finds Cancer Mortality Rates Correlate With Geography as Well as Known Behavioral Risk Factors

Researchers at Case Western Reserve University have found that risk factors historically linked to cancer mortality vary regionally across the lower 48 United States—such that they believe those differences should be considered in developing tailored public-health interventions. Dong et al...

ASCO Announces Election Candidates, Voting Opens on November 2

The ASCO Nominating Committee has selected 11 distinguished members as candidates for open leadership positions within the Society. Voting members are urged to vote in the election beginning November 2, 2022. Voting will close on December 6, 2022. President-Elect (4-year term) Robin Zon, MD, FACP, ...

supportive care
symptom management

FDA Approves Sodium Thiosulfate to Reduce the Risk of Ototoxicity Associated With Cisplatin

On September 20, the U.S. Food and Drug Administration (FDA) approved sodium thiosulfate (Pedmark) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients aged 1 month and older with localized (nonmetastatic) solid tumors. Efficacy was evaluated in two multicenter,...

hepatobiliary cancer

Individuals of Mexican Descent May Have Higher Risk of Liver Cancer With Each Successive Generation

Studies show that Hispanic individuals have higher incidence rates of developing liver cancer and higher mortality rates—by 50% or more—than non-Hispanic White individuals for several cancers, including liver cancer. A new study investigating hepatocellular carcinoma among successive generations of ...

prostate cancer
genomics/genetics

Prostate Tumor Biology May Be Influenced by Genetic Ancestry

Certain genetic variants found in prostate tumors of men of African descent were associated with African ancestry, according to two studies presented at the 15th American Association for Cancer Research (AACR) Conference on the Science of Cancer Health Disparities in Racial and Ethnic Minorities...

issues in oncology

Do LGBTQI+ Patients With Cancer Receive Mental Health Information Tailored to Their Needs?

Although customized health education materials for lesbian, gay, bisexual, transgender, queer, and intersex (LGBTQI+) cancer survivors may play a pivotal role in their experiences throughout their cancer care continuum, a study by Burnett et al has found that regardless of their satisfaction with...

covid-19

Antibody Response to Three-Dose COVID-19 mRNA-1273 Vaccination Schedule in Immunocompromised Patients With Hematologic Cancers

In a Dutch prospective observational cohort study reported in JAMA Oncology, Haggenburg et al found that a third dose of the COVID-19 mRNA-1273 vaccine increased antibody levels in immunocompromised patients with hematologic cancers overall to levels comparable to those observed in healthy controls ...

breast cancer

Neoadjuvant Endocrine Therapy May Elicit Differential Responses in Black vs White Women With Breast Cancer

Black women treated with neoadjuvant endocrine therapy for breast cancer were more likely to benefit than White women if treated at an earlier disease stage, but less likely to benefit than White women if treated at a later disease stage, according to results presented at the 15th American...

leukemia

Many Families of Children With Leukemia May Experience Food Insecurity That Is Not Alleviated by Federal Assistance Program

Nearly one in four families of pediatric patients with acute lymphoblastic leukemia (ALL) enrolled in a clinical trial experienced food insecurity, and almost half of the families eligible for the Supplemental Nutrition Assistance Program (SNAP) did not receive benefits. In addition, receiving SNAP ...

lung cancer
immunotherapy

Real-World Experience With Durvalumab at the Mayo Clinic Mirrors PACIFIC Findings

Concurrent chemoradiation followed by durvalumab has become the standard of care in patients with unresectable, locally advanced non–small cell lung cancer (NSCLC), based on the PACIFIC trial.1 But clinical trials have predetermined inclusion and exclusion criteria, and they evaluate selective...

issues in oncology

New Study Shows Sugar-Sweetened Drinks May Increase Risk of Cancer Mortality

In a large study led by researchers at the American Cancer Society (ACS), men and women who drank two or more servings of sugar-sweetened beverages per day had a 5% increased risk of death from an obesity-related cancer, including gastrointestinal, postmenopausal breast, endometrial, and kidney...

multiple myeloma

Novel Photon-Counting CT May Improve Myeloma Bone Disease Detection

New computed tomography (CT) technology paired with artificial intelligence (AI)-based noise reduction may offer superior detection of bone disease associated with multiple myeloma at lower radiation doses than conventional CT, according to a recent study published by Baffour et al in Radiology....

colorectal cancer

Recurrence-Free Survival as Surrogate for Overall Survival in Patients Undergoing Resection of Colorectal Liver Metastases

In a single-center retrospective study and a separate meta-analysis reported in The Lancet Oncology, Ecker et al found low correlations between recurrence-free survival and overall survival among patients undergoing resection of colorectal cancer liver metastases. As stated by the investigators,...

issues in oncology
health-care policy

Compliance of NCI-Designated Cancer Centers With January 2021 CMS Price Transparency Requirements

In a study reported in JAMA Surgery, Childers et al found that only one-third of hospitals with National Cancer Institute (NCI)-designated cancer center status were fully compliant with Centers for Medicare & Medicaid Services (CMS) price transparency requirements instituted in January 2021....

breast cancer

Reporting of Hispanic Ethnicity and Race in Breast Cancer Studies: National Cancer Database Analysis

In a National Cancer Database (NCDB) analysis reported in a research letter in JAMA Oncology, Bazan et al found that Hispanic ethnicity was reported in patient demographics or results in less than half of studies in breast cancer, with a smaller proportion categorizing race and ethnicity into...

lung cancer

National Lung Screening Trial Results Highlight Importance of Lifelong Follow-up

Approximately 6% of patients with stage I to III lung cancer develop a second primary lung cancer within 5 years of their initial diagnosis, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer.1 Analysis of data...

Highlights From the ESMO Congress 2022

The ESMO Congress 2022 took place in Paris from September 9 to 13. In this episode, we highlight key research presented at the meeting. We’ll first hear from the presenting author of Abstract LBA1 on the effect of air pollutants on the risk of non–small cell lung cancer. Then, we’ll hear from a...

bladder cancer
immunotherapy

New Research From Cohort K of the EV-103 Trial of Enfortumab Vedotin for Patients With Urothelial Cancer

Researchers from Memorial Sloan Kettering (MSK) Cancer Center shared data on a treatment option for patients with bladder cancer at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA73). Jonathan E. Rosenberg, MD, medical oncologist and Chief of the Genitourinary Oncology...

cost of care
breast cancer
colorectal cancer
lung cancer
prostate cancer

Costs of Cancer Treatment for Younger, Privately Insured Patients

A new, large study led by researchers at the American Cancer Society (ACS) and The University of Texas MD Anderson Cancer Center showed the rising costs of cancer treatment led to increases in total costs of care, and when compounded with greater cost-sharing, increased out-of-pocket costs for...

breast cancer
cost of care

Cost-Effectiveness of Chemotherapy Sequences in Metastatic Breast Cancer According to Prior Therapy Exposure

In a modeling study reported in the Journal of Clinical Oncology, Stephanie B. Wheeler, PhD, MPH, and colleagues identified the most cost-effective sequences of single-agent chemotherapy regimens among patients with endocrine-refractory or triple-negative metastatic breast cancer according to prior ...

colorectal cancer

Use of Trimodality Therapy in Stage II/III Rectal Cancer in the United States: 10-Year Period

In a retrospective cohort study reported in JAMA Oncology, Hagen F. Kennecke, MD, and colleagues found that among U.S. patients with clinical stage II/III rectal cancer diagnosed between 2006 and 2016 who received trimodality therapy, use of postoperative chemoradiation therapy (CRT) decreased and...

prostate cancer

Rezvilutamide vs Bicalutamide Combined With ADT in High-Volume Metastatic Hormone-Sensitive Prostate Cancer

As reported in The Lancet Oncology by Gu et al, interim analyses of the phase III CHART trial have shown improved radiographic progression-free survival and overall survival with the novel androgen receptor inhibitor rezvilutamide vs bicalutamide when both were combined with androgen-deprivation...

lung cancer

Tony S.K. Mok, MD, on NSCLC: Review of Recent Data From the SUNRISE and ORIENT-31 Trials

Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses two late-breaking abstracts presented at ESMO 2022: the phase II SUNRISE study, which compared sintilimab plus anlotinib vs platinum-based chemotherapy as first-line therapy in patients with metastatic non–small cell lung cancer...

breast cancer
survivorship

Matteo Lambertini, MD, PhD, on Oncofertility Care for Young Women With Breast Cancer

Matteo Lambertini, MD, PhD, of the University of Genova and Policlinico San Martino Hospital, talks about why oncofertility counseling should now be considered mandatory in the care of young women with breast cancer. Among the treatments he recommends offering are oocyte/embryo cryopreservation (or ...

skin cancer
immunotherapy

Georgina V. Long, MD, PhD, on Melanoma: Findings on Circulating Tumor DNA, Disease Recurrence, and Immunotherapy

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, discusses results from the CheckMate 915 trial, an analysis of the pretreatment circulating tumor DNA, along with other clinical and translational baseline factors, and their association with disease recurrence in patients with stage...

Advertisement

Advertisement



Advertisement